Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292

@inproceedings{Furugaki2011ErlotinibIO,
  title={Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292},
  author={Koh Furugaki and Yoichiro Moriya and Toshiki Iwai and Keigo Yorozu and Mieko Yanagisawa and Kumiko Kondoh and Kaori Fujimoto-Ohuchi and Kazushige Mori},
  booktitle={Clinical & Experimental Metastasis},
  year={2011}
}
Previous preclinical and clinical findings have suggested a potential role of epidermal growth factor receptor (EGFR) in osteoclast differentiation and the pathogenesis of bone metastasis in cancer. In this study, we investigated the effect of erlotinib, an orally active EGFR tyrosine kinase inhibitor (TKI), on the bone invasion of human non-small-cell lung cancer (NSCLC) cell line NCI-H292. First, we established a novel osteolytic bone invasion model of NCI-H292 cells which was made by… CONTINUE READING